A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
| Principal Investigator: | Peter Kozuch, MD |
| Time frame of study: | Ongoing |
| Location of Study: | Beth Israel Medical Center |
| Contact: | Continuum Cancer Research Program |
Summary:
This study aims to test the effectiveness and safety of GS-6624 at different
dose levels. GS-6624 is an experimental agent being developed to treat
many different diseases. We want to find out what effects, good and/or
bad, GS-6624 has on you and your metastatic pancreatic adenocarcinoma
when it is given with Gemcitabine. Gemcitabine is approved by the FDA
for pancreatic adenocarcinoma.
Eligibility of Participants:
• 18 years of age or older
• Initial diagnosis of metastatic disease must have occurred = 6
weeks prior to the completion of the screening
• The presence of measurable metastatic pancreatic cancer documented
by CT or MRI
Please call for more information.
Copyright © 2008